alexa Pharmacogenomics-Guided Approaches to Avoiding Adverse Drug Reactions | OMICS International | Abstract
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Pharmacogenomics-Guided Approaches to Avoiding Adverse Drug Reactions

Xiao-Wu Chen1, Wanqing Liu2 and Shu-Feng Zhou3*
1Department of General Surgery, The First People’s Hospital of Shunde, Southern Medical University, Shunde, Guangdong 528300, China
2Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, USA
3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, USA
Corresponding Author : Shu-Feng Zhou, MD, PhD
Associate Vice President for Global Medical Development
Department of Pharmaceutical Sciences
College of Pharmacy
University of South Florida
12901, Bruce B Downs Blvd.
Tampa, FL 33612, USA
Tel: 813 974-6276
Fax: 813 905-9885
E-mail: [email protected]
Received November 08, 2012; Accepted November 27, 2012; Published November 30, 2012
Citation: Chen XW, Liu W, Zhou SF (2012) Pharmacogenomics-Guided Approaches to Avoiding Adverse Drug Reactions. Clinic Pharmacol Biopharm. 1:104. doi:10.4172/2167-065X.1000104
Copyright: © 2012 Chen XW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Adverse drug reactions (ADRs) are one of the major causes of patient morbidity and mortality. Pharmacogenomics is the study of how individual response to drugs is affected by genetic mutations at the genome level. There is clinical evidence that polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets (e.g. receptors & enzymes) can lead to the occurrence of ADRs. In addition, mutations of certain genes can precipitate ADRs. Over the past years, genome-wide association studies (GWAS) have identified a number of common and rare variants that are associated with increased risk of ADRs. As affordable and reliable genetic testing tools become available to physicians, pharmacogenomics looks promising to facilitate individualization of drug therapy and as a result, this will maximize the therapeutic efficacy of drugs in patients while minimizing the occurrence of ADRs.

Keywords

Recommended Conferences

33rd World Congress on Pharmacology

Barcelona, Spain
Share This Page
Top